Abstract
Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failure, primary congenital heart diseases and sepsis and cancer-associated cardiac dysfunction. Most studies reported improvement in ventricular function, central venous oxygen saturation, serum lactate levels or cardiac index. The 5 randomized studies published so far have all been performed in cardiac surgery and suggest a beneficial effect on hemodynamic data with no effect on intensive care unit stay, hospital stay or survival. Side effects (e.g. hypotension) were reported. This inodilator merits to be investigated with further randomized trials focusing on clinically relevant outcomes.
Keywords: Cardiac surgery, chronic heart failure, congenital heart diseases, hemodynamic effect, levosimendan, paediatric patients, systematic review.
Current Vascular Pharmacology
Title:A Systematic Review on Levosimendan in Paediatric Patients
Volume: 13 Issue: 1
Author(s): Simona Silvetti, Paolo Silvani, Maria Luisa Azzolini, Roberto Dossi, Giovanni Landoni and Alberto Zangrillo
Affiliation:
Keywords: Cardiac surgery, chronic heart failure, congenital heart diseases, hemodynamic effect, levosimendan, paediatric patients, systematic review.
Abstract: Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failure, primary congenital heart diseases and sepsis and cancer-associated cardiac dysfunction. Most studies reported improvement in ventricular function, central venous oxygen saturation, serum lactate levels or cardiac index. The 5 randomized studies published so far have all been performed in cardiac surgery and suggest a beneficial effect on hemodynamic data with no effect on intensive care unit stay, hospital stay or survival. Side effects (e.g. hypotension) were reported. This inodilator merits to be investigated with further randomized trials focusing on clinically relevant outcomes.
Export Options
About this article
Cite this article as:
Silvetti Simona, Silvani Paolo, Azzolini Maria Luisa, Dossi Roberto, Landoni Giovanni and Zangrillo Alberto, A Systematic Review on Levosimendan in Paediatric Patients, Current Vascular Pharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570161112666141127163536
DOI https://dx.doi.org/10.2174/1570161112666141127163536 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Determinants of Human Coronary Collaterals
Current Cardiology Reviews Patent Ductus Arteriosus in Extreme Prematurity: Role of Echocar-diography and Other Imaging Techniques
Current Pediatric Reviews Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?
Current Pharmaceutical Design Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD
Endocrine, Metabolic & Immune Disorders - Drug Targets Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets Gestational Programming of Offspring Obesity: A Potential Contributor to Alzheimers Disease
Current Alzheimer Research Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi: A Sulfated Glycoprotein Antigen as Relevant Candidate for Vaccine Development and Drug Target. A Review
Current Medicinal Chemistry Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews